Zydus to present EVIDENCES IV clinical trial results of Saroglitazar Magnesium in NAFLD, NASH

23 Oct 2019 Evaluate

Zydus Cadila is going to present the data of its EVIDENCES IV clinical trial of Saroglitazar Magnesium, at The Liver Meeting 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, USA from November 8-12,, 2019.

Earlier Zydus had reported that the EVIDENCES IV clinical trial had achieved the primary end-points in patients with NAFLD and NASH.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

948.20 -2.75 (-0.29%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.